PSP Research’s Compass Therapeutics CMPX Stock Holding History

PSP Research’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$159K	–	79
2026 Q1	$159K	Buy	+30,000	New	+$173K	0.11%	75

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PSP Research's CMPX Position: Q2 2026 in Review

PSP Research sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 30,000 shares — an estimated $159K sold.

PSP Research first reported a position in CMPX in Q1 2026 and held it in 1 quarter. The position peaked at $159K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

PSP Research reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
PSP Research sold 30,000 Compass Therapeutics shares in Q2 2026, an estimated $159K.
PSP Research first reported a position in Compass Therapeutics in Q1 2026 and held it in 1 quarter.
PSP Research's Compass Therapeutics position peaked at $159K in Q1 2026.
215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.